surpass 4 tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial New SURPASS-CVOT Ad Hoc Analysis:

SKU: 22560826500

Pay in 4 interest-free payments of $5.18 Learn more

Live Spec

New SURPASS CVOT Ad Hoc Analysis: Tirzepatide outperforms dulaglutide for reducing cardiorenal risks in T2D patients : r Zepbound The Association Between Tirzepatide Versus Insulin Glargine and NT proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4 Circulation Once weekly tirzepatide versus once daily insulin degludec as add on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS 3): a randomised, open label, parallel group, phase 3 trial The Lancet Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program Cardiovascular Diabetology Springer Nature Link

Store: finou-maps.com · Domain: finou-maps.com